bg image

National Center of Genetics

The National Center of Genetics (NCG) of the LNS is committed to provide genetic counselling and diagnosis of genetic diseases and to carry out molecular and genetic analysis of cancers.

The National Center of Genetics consists of 3 services:

  • Clinical Genetics Service
  • Cytogenetics & Hemato-Oncogenetics Service
  • Molecular Genetics Service

The National Center of Genetics (NCG) holds a comprehensive purpose. Its primary mission, as the exclusive provider of genetic services in Luxembourg, is to make the full spectrum of medical genetic services accessible to all individuals living or working in Luxembourg. Beyond this central diagnostic role, the NCG also contributes to the fields of teaching and research. Since its establishment in 2017, the NCG has experienced significant and rapid growth to fulfill these ambitious goals.


Clinical Genetics Service

Genetic counselling aims to provide information to patients and their families about their genetic disease: its nature, mode of transmission, risk for other family members, genetic testing to establish or confirm the diagnosis. Patients receive oral and written information (medical reports and/or specific information) about the disease. These consultations cover constitutional genetic disorders (disability, intellectual disability, cystic fibrosis and the like), preconception and prenatal genetic counselling, predictive genetic counselling (diagnosis of a genetic disease before its symptoms appear) and genetic predispositions to cancers.

The Clinical Genetics Service provides genetic consultations and works closely with all hospitals, private practitioners, and other healthcare providers, including ALAN. This close collaboration aims to manage patients with genetic disorders effectively. Additionally, our clinical geneticists contribute their expertise to various interdisciplinary case meetings, fostering a strong clinical collaboration between the NCG and the Centre Hospitalier de Luxembourg (CHL).


The Cytogentics & Haemato-Oncognetics Service covers all aspects of human genetics. This includes pre-and postnatal diagnosis of hereditary genetic diseases, newborn screening, and cytogenetic diagnosis of hematological malignancies. We employ a broad range of technologies and have introduced several new tests, from traditional and molecular cytogenetics (including Fluorescence in situ Hybridization – FISH and array Comparative Genomic Hybridization – array CGH) to We have witnessed a substantial increase in diagnostics, both in the number of analyses performed and the spectrum of diagnostic tests offered. A significant milestone was the establishment of the state-of-the-art next-generation-sequencing facility, the LUXGEN Genome Center, in collaboration with the Luxembourg Institute of Health (LIH). This collaboration enabled us to implement NGS-based diagnostic at the NCG for lung cancer, hereditary cancer, and non-invasive prenatal testing (NIPT). Moreover, we have adopted cytogenetic diagnostics for all cases of hematological neoplasia and have eliminated primary outsourcing of those cases.

Molecular Genetics Service

Molecular genetics includes a variety of PCR-based molecular genetic tests for patients with mono-genetic disorders like Cystic Fibrosis. In addition, the service provides and state-of-the-art next-generation sequencing (NGS) of gene panels for detection of somatic mutations in cancer tissue samples from patients diagnosed with a variety of cancers.  the service also offers exome and genome sequencing & analyses for patients with constitutional diseases and for children with rare diseases.



Cytogenetics & Hemato-Oncogenetics

The genetic diagnostic laboratories command the skills and tools needed to diagnose the most common genetic diseases. The investigation methods rely on cytogenetic techniques (karyotyping, FISH, aCGH) and molecular biology. Diseases investigated therefore involve chromosomal abnormalities (trisomies, deletions, duplications and the like), monogenic diseases (cystic fibrosis, haemoglobin disorders and the like) and genetic predisposition to cancers (breast and ovarian cancer, Lynch Syndrome and the like).

This diagnostic activity also includes NIPT and prenatal diagnosis.

There are thousands of genetic diseases, some of which are very rare. To allow access to diagnosis to a maximum of patients, the department of genetics collaborates with accredited foreign laboratories and send them samples together with pertinent clinical information.

The genetic analysis of cancer types

The NCG is also responsible for the genetic analysis of cancer types. All cancers have acquired genetic abnormalities responsible for the transformation of cancer cells. The identification of these anomalies may contribute to diagnosis, define the prognosis and severity of the disease, serve as a guide for treatment and provide access to specific ‘targeted’ drugs. It can also allow monitoring of the therapeutic response and detection of a resistance mechanism.

This activity, originally developed for the diagnosis of haematologic cancers (leukaemias and lymphomas), is gradually extending to all types of cancers with the advent of new therapeutic agents and molecular tests called ‘companion’ tests’ that can predict response or resistance to these treatments. The molecular and genetic diagnostic activity of solid tumours is developed and carried out in collaboration with the National Center of Pathology.

Molecular Genetics

The technical platform of molecular genetics is a component of the center. This platform is committed to developing methods for genetic and molecular analysis for the diagnosis of genetic diseases and the genetic study of cancer. Toward this end, the platform has developed expertise especially in next-generation DNA sequencing methods (NGS) and bioinformatics tools for the analysis of DNA sequences. Genomic medicine is actually burgeoning: it involves the analysis of large gene panels from a patient or a tumour in order to acquire a large amount of genetic information and thus speed up the diagnostic process. Recently, the platform has implemented the first NGS analysis of genetic panels for diagnosis in oncology (colorectal tumours, lung tumours and the like) and for genetic predisposition to cancer.

the team

LNS – Clinical genetics and National Center of Genetics